Privacy Policy

Login

Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av MFN som distributionsmotor?

Läs mer!

05:51:25 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

IRLAB Therapeutics Q4 2022 - Still Plenty of Value

Prenumeration

IRLAB Therapeutics Q4 2022 - Still Plenty of Value

2023-02-24 09:45:00

Redeye returns with a research update following the Q4 report and recent events in the company. We slightly adjust our base case and conclude that 2023 will be an important year, most notably to present the full mesdopetam data and regain investor confidence.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Redeye

Bifogade filer

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden